A Phase II Trial of VAD ( Vincristine , Doxorubicin and Dexamethasone ) Chemotherapy for Previously Untreated Multiple Myeloma / 대한내과학회지
Korean Journal of Medicine
;
: 75-84, 1999.
Article
in Korean
| WPRIM
| ID: wpr-53996
ABSTRACT
OBJECTIVE:
The combination of vincristine and doxorubicin by continuous infusion was reported to reduce tumor mass more rapidly than standard regimens, which maybe a result of effect on more slowly proliferating plasma cells. We conducted a phase II study to determine the activity and safety of VAD (vincristine, doxorubicin, dexamethasone) chemotherapy, in which vincristine and doxorubicin are administered as a continuous infusion, for previously untreated multiple myeloma.METHODS:
VAD chemotherapy (vincristine 0.4 mg/day 24 hour-continuous infusion, days 1~4; doxorubicin 9 mg/m2/day 24 hour-continuous infusion, days 1~4; dexamethasone 40 mg/day p.o. days 1~4) was given to eligible patients every 4 weeks and we assessed response and toxicity of the regimen.RESULTS:
Between January 1991 and March 1997, total 25 patients entered this trial and 22 were evaluable. The complete response rate was 14%(3/22) and overall response rate was 59%(13/22, 95% C.I. 38~80%). The time to response was 1.0~6.8(median 2.9) months. Progression free survival was 2~39+(median 11.5) months and the overall survival was 3+~42+(median 19.7) months. Toxicities of VAD regimen were leukopenia, infection, stomatitis and neurotoxicity, but there was no treatment-related death.CONCLUSION:
VAD chemotherapy was tolerable, but not more active than the alkylating agent-based chemotherapy as a front-line treatment for the patients with multiple myeloma. But, because of its rapid response and relatively mild myelotoxicity, it could play a role for advanced or highly complicated disease and for remission induction before consolidation with high-dose chemotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma Cells
/
Stomatitis
/
Vincristine
/
Remission Induction
/
Dexamethasone
/
Doxorubicin
/
Disease-Free Survival
/
Drug Therapy
/
Leukopenia
/
Multiple Myeloma
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
1999
Type:
Article
Similar
MEDLINE
...
LILACS
LIS